A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir.

Claudia Ramirez-SanchezJade KozuchMita M ShahJennifer BerumenKristin MekeelGabriel SchnickelMahnaz TaremiEugene GoltsKamyar AfsharEric D AdlerVictor PretoriusSaima Aslam

Published in: Open forum infectious diseases (2022)

A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

Keyphrases

hepatitis c virus
human immunodeficiency virus
heart failure
kidney transplantation
atrial fibrillation
patients undergoing
hiv infected
antiretroviral therapy
hiv infected patients